MARATTO

article · Neurology

Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: A Meta-analysis With Reconstructed Individual Patient Data (P4-20.010)

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

To compare the efficacy and safety of Bruton's tyrosine kinase (BTK) inhibitors against placebo and teriflunomide in patients with Multiple Sclerosis (MS).

Research topics

  • Chronic Lymphocytic Leukemia Research
  • Multiple Myeloma Research and Treatments
  • Multiple Sclerosis Research Studies

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1212/wnl.0000000000217245

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.